AC Immune gets $22M for tau-targeting Alzheimer’s vaccine
By Cormac Sheridan
Friday, January 10, 2014
AC Immune SA raised CHF20 million (US$22 million) in a Series D round that will fund clinical development of a therapeutic vaccine for Alzheimer’s disease, ACI-35, which targets a phosphorylated species of tau protein thought to be involved in the progression of the condition.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.